Doctor’s Guide -- STOCKHOLM, Sweden -- September 2, 2010 -- Treatment with olmesartan failed to reduce the burden of atrial fibrillation among patients who recorded more than 80,000 tele-electrocardiogram (ECG) reports in the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, researchers reported here on August 31 at the European Society of Cardiology Congress 2010 (ESC).
